Latest News

  • To Realize The Potential Of Exosomes, We Need New Technology And Standards

    Diagnostics World Contributed Commentary | Exosome research has been a relatively niche field for some years now, but today there is growing enthusiasm among a much broader community about the diagnostic, prognostic, and therapeutic potential of these vesicles. Following on the heels of circulating tumor cells and cell-free DNA, exosomes represent the next great opportunity for liquid biopsy applications.

    Dec 18, 2018
  • Accelerating Personalized Healthcare with High Performance Computing in the Cloud

    Diagnostics World Contributed Commentary | Major factors contributing to the acceleration of personalized healthcare in recent years come from advances in high-performance computing (HPC), data analytics, machine learning, and artificial intelligence, enabling scientists now to perform the most sophisticated simulations in genomics, proteomics, and many other fields, using methods like genome analysis, molecular dynamics, and more general computer aided analysis methods widely applied and proven in other areas of scientific and engineering modeling. We demonstrate the impact of computer simulations on personalized health care and present two research projects aiming at living heart and brain simulations.

    Dec 13, 2018
  • In Remote Villages Surprising New Measures Save Children With Malaria

    The New York Times | Malaria quickly kills toddlers. But rapid diagnostic tests, a new suppository drug and bicycle ambulances can buy enough time to get stricken children to hospitals.

    Dec 10, 2018
  • Pushing Past The Stigma: Spinal Taps For Early Alzheimer’s Diagnosis

    Diagnostics World Contributed Commentary | Growing evidence suggests biological markers of Alzheimer’s disease may begin forming decades before an individual begins experiencing symptoms. Because of this, researchers are finding ways to detect the disease earlier and with more accuracy than standard diagnostic methods.

    Dec 10, 2018
  • Insight Genetics Launches Test To Categorize Triple Negative Breast Cancer

    Diagnostics World Brief | Insight Genetics has launched Insight TNBCtype, a new test for categorizing triple negative breast cancer (TNBC) tumors into distinct molecular subtypes through its wholly owned CLIA- and CAP-accredited lab, Insight Molecular Labs.  Insight TNBCtype is the first CLIA-validated assay for TNBC molecular subtyping, and the company believes it will enable prospective clinical trials with pharmaceutical, biotechnology, and academic medical institutions and advance targeted therapies for TNBC patients, addressing a significant unmet need in oncology today.

    Dec 7, 2018
  • Healthcare Organizations Form Synaptic Health Alliance, Explore Blockchain’s Impact On Data Quality

    Diagnostics World | Quest Diagnostics, in partnership with Humana, MultiPlan, and UnitedHealth Group’s Optum and UnitedHealthcare, have launched a pilot program that applies blockchain technology to improve data quality and reduce administrative costs associated with changes to healthcare provider demographic data.

    Dec 5, 2018
  • Biocartis, AstraZeneca Enter Into Agreement Aimed At Faster Lung Cancer Biomarker Results

    Diagnostics World News Brief | Biocartis announced it has entered into an agreement with AstraZeneca. The goal of the agreement will be to obtain faster lung cancer molecular diagnostic biomarker results in Europe.

    Nov 30, 2018
  • BioIVT, Illumina, Certara, And More: News From November 2018

    Diagnostics World | November featured news, products, and partnerships from around the diagnostics community from numerous companies, universities, and organizations, including BioIVT, Illumina, Certara, and more.

    Nov 28, 2018
  • It's Lights Out For Novartis And Verily's Glucose Monitoring “Smart Lens” Project

    Forbes | Alphabet's Verily and Novartis eye-care subsidiary Alcon are pulling the plug on the glucose monitoring "smart lens" device the two companies had been attempting to build since 2014, according to a post by Verily chief technical officer Brian Otis on the company's website Friday.

    Nov 19, 2018
  • The Big Push For Early Alzheimer’s Diagnostics

    Diagnostic World News Today’s diagnostic methods for Alzheimer's disease, which evaluate cognition using traditional pen and paper tests, are less than ideal. The results can be combined with physical health, medical history, and information from family members or caregivers. If a patient does not perform well on a cognitive test, there are other potential causes of memory loss that still need to be ruled out. Thankfully there's been a recent push to advance Alzheimer's disease diagnosis.

    Nov 15, 2018